Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.35 |
| ▸ | JAK3 | P52333 | 5/20 | 0.34 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 2/20 | 0.32 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.31 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20358834 | 1.00 | BTK (0.35) | BTKJAK3PDE2AITGB2ICAM1 | |
| SCHEMBL20359192 | 0.93 | ITGB2 (0.38) | BTKPDE2AITGB2ICAM1ITGAL | |
| SCHEMBL20359195 | 0.93 | ITGB2 (0.38) | BTKPDE2AITGB2ICAM1ITGAL | |
| SCHEMBL20359000 | 0.91 | ACACB (0.37) | JAK3PDE2AIDH1CDK13CDK12 | |
| SCHEMBL20358998 | 0.91 | ACACB (0.37) | JAK3PDE2AIDH1CDK13CDK12 | |
| SCHEMBL20359287 | 0.86 | CDK13 (0.38) | PDE2AIDH1CDK13CDK12 | |
| SCHEMBL20359286 | 0.86 | CDK13 (0.38) | PDE2AIDH1CDK13CDK12 | |
| SCHEMBL20358892 | 0.83 | ACACB (0.39) | PDE2AITGB2ICAM1ITGAL | |
| SCHEMBL20358894 | 0.83 | ACACB (0.39) | PDE2AITGB2ICAM1ITGAL | |
| SCHEMBL20358472 | 0.82 | BTK (0.51) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | claimed |
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LCK | BTK 1/4885JAK3 16/4885PDE2A 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.